<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.webmd.com/dna/the-turning-point/afib');</script>

        <script> var body_html = '<body> <header ></header> <div ><div ><div > <div > <div > <h1 ><a >THE TURNING POINT</a></h1> <div > <ul> <li> <a > AFIB </a> </li> <li> <a > DVT/PE </a> </li> <li> <a > CAD </a> </li> </ul> </div> </div> <div > <div > <div > <div > <p >Living well with AFib starts with self-advocacy</p> <div > <p>JANET</p> <p>Age 72</p> <p>Diagnosed with AFib in 2014</p> </div> </div> </div> <div > <div > <p >“This year's our 50th wedding anniversary. We’re getting the whole family and grandkids and everything together,” says Janet S., age 72. Janet is celebrating this milestone on a family trip where the whole clan plans to listen to live music and go to amusement parks.</p> <p >In 2014, while getting bloodwork done for an unrelated procedure, Janet was diagnosed with AFib. Luckily, her procedure went well, but her AFib remained since it is a separate condition. At that point, Janet worked with her doctor to understand her diagnosis while also doing her own research.</p> </div> </div> </div> <div > What is AFib? <p>AFib is an irregular heartbeat that keeps the upper and lower chambers of the heart from working together. This can cause blood to pool in the heart, which can lead to complications like blood clots.</p> <p >Up to 6.1 MILLION Americans are estimated to have atrial fibrillation (AFib), a condition that causes:</p> <div > <div > <div > <p >IRREGULAR HEARTBEAT</p> </div> <div > <p >HEART PALPITATIONS</p> </div> </div> <div > <p >Which lead to:BLOOD POOLING IN THE HEART</p> </div> <div > <p >Causing:A BLOOD CLOT TO FORM</p> </div> </div> <p>"The causes of AFib are varied," explains Dr. Sanjum Sethi, a cardiologist at Columbia University Medical Center. Other causes include high blood pressure, sleep apnea, excessive consumption of alcohol, being overweight, smoking, diabetes, a family history of AFib, and other heart conditions. </p> <div > <p >“If you have a heart valve problem or prior cardiac surgery, those could predispose you to AFib, but most commonly, it’s a disease of aging…as we age, the incidence [of AFib] increases quite dramatically."</p> <p >Dr. Sanjum Sethi</p> </div> <div > Janet's Stroke Risk <p>Janet's doctor explained the CHA<sup >2</sup>DS<sup >2</sup>-VASc score to her, which is based on certain conditions that determine risk for stroke. “The scoring system helps us determine what the actual risk is for developing stroke if you have AFib. Not every patient who has AFib is at equal risk for stroke. The CHA<sup >2</sup>DS<sup >2</sup>-VASc score allows us to determine which patients will benefit the most from receiving anticoagulation," explains Dr. Sethi. Janet has a score of 3 out of 9, with her age, gender, and type II diabetes as the three factors.</p> </div> <p >You can find out your score by using this calculator.</p> <div > <div > <p><span>CHA<sup >2</sup>DS<sup >2</sup>-VASc: KNOW YOUR RISK</span></p> </div> <div > <p>Add points below for each condition you have</p> </div> <div > <div > <div > Points </div> <div > Condition </div> </div> <div > <div > Points </div> <div > Condition </div> </div> </div> <div > <div > <div > <div> <h2>CONGESTIVE HEART FAILURE</h2> <p>Signs/symptoms of heart failure confirmed with test of heart failure</p> </div> </div> </div> <div > <div > <div> <h2>HIGH BLOOD PRESSURE</h2> <p>Resting blood pressure &gt;140/90 on at least 2 occasions or on blood pressure meds</p> </div> </div> </div> </div> <div > <div > <div > <div> <h2>AGE 65 TO 74 YEARS</h2> </div> </div> </div> <div > <div > <div> <h2>DIABETES MELLITUS</h2> <p>Fasting blood sugar &gt;125 mg/dL or on medications or insulin</p> </div> </div> </div> </div> <div > <div > <div > <div> <h2>STROKE</h2> <p>Includes any history of stroke</p> </div> </div> </div> <div > <div > <div> <h2>VASCULAR DISEASE</h2> <p>Prior heart attack, peripheral artery disease, or aortic plaque</p> </div> </div> </div> </div> <div > <div > <div > <div> <h2>AGE 75 YEARS OR OLDER</h2> </div> </div> </div> <div > <div > <div> <h2>SEX CATEGORY (FEMALE)</h2> <p>Female gender means a higher risk</p> </div> </div> </div> </div> </div> <div > <div ><p>The American Heart Association recommends anticoagulation with a blood thinner for a score of 2 OR HIGHER.</p></div> </div> <div > <div ><p>REMINDER: Even if you are taking medicine to treat your AFib and not experiencing symptoms, YOUR STROKE RISK WILL CONTINUE TO INCREASE OVER TIME.</p></div> </div> <div > <div ><p>YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> <div > Symptoms <p>Common symptoms of AFib are a rapid and irregular heartbeat, heart palpitations, chest pain or pressure, dizziness, fainting, shortness of breath, or fatigue—but some people experience no symptoms at all. When Janet was first diagnosed, she would experience short periods of heart racing but was lucky that her symptoms never reached extreme levels. </p> </div> <div > <p >“AFib is tricky in the sense that some people are very symptomatic, and some people have no symptoms at all. AFib is an electrical problem of the heart where the top chamber is beating a lot faster than the bottom chamber. The body is often able to compensate for the electrical problem, so you may experience no symptoms at all." </p> <p >Dr. Sanjum Sethi</p> </div> <p>Because of all her research, Janet was aware that AFib can cause blood clots, which can lead to stroke, so she made the decision with her doctor to start an aspirin regimen to lower her risks.</p> <div > People with AFib are5 TIMES MORE LIKELY to have a stroke </div> <p>Stroke is a serious consequence of AFib. Complications from AFib, such as heart palpitations and irregular heartbeats, can cause blood to pool in the heart, where a clot can develop. </p> <h3 >Why blood clots matter:</h3> <div > <div > <h3>CLOTS CAN TRAVEL FROMTHE HEART TO THE BRAIN</h3> </div> <div > <h3>CREATING BLOCKAGES</h3> </div> <div > <h3>WHICH CAN CAUSE A STROKE</h3> </div> </div> <p>Even if you are treating your AFib and feeling fine, your stroke risk continues to increase over time. That’s why it’s important to periodically review your <span>CHA<sup >2</sup>DS<sup >2</sup>-VASc score with your doctor.</span></p> </div> <div > <div > <h3 >Janet's Turning Point</h3> </div> <div > <p>After initially treating AFib with aspirin, Janet saw a doctor who recommended a blood thinner called XARELTO<sup>®</sup>. While aspirin was once considered a treatment for those at low risk for stroke, the AHA no longer recommends aspirin for the treatment of AFib, regardless of risk level. As her own best advocate, Janet stays up-to-date on the benefits and risks of taking XARELTO<sup>®</sup>. Her husband also plays a large role in her health.</p> <div > <p >“He really wants me to take XARELTO<sup>®</sup> because he doesn't want me to have a stroke either. We support each other. He'll remind me to take my meds after dinner."</p> <p >Janet</p> </div> <p>With 6 children and 15 grandchildren, there's no shortage of people who are counting on Janet to stay healthy. “I know how devastating [strokes] can be and I did think about my children and grandchildren and my husband…I thought if I could avoid having one, that would be good—live a longer life without impairment, that would be great. I know some people that've had strokes, and it's really tough," says Janet. Along with taking XARELTO<sup>®</sup>, Janet now exercises more. She belongs to a local gym and goes on a vigorous walk once a week. This has also allowed her to take advantage of her city's metro park system. </p> <p>Janet is proof that working with your doctor is integral to managing AFib-related stroke and blood clots. A combination of her own research and conversations with various doctors has led her to a plan that includes once-daily XARELTO<sup>®</sup> to lower her risk for stroke. <span >Because XARELTO<sup>®</sup> is a blood thinner, it helps prevent or reduce blood clotting, which significantly reduces the risk of stroke in people with AFib not caused by a heart valve problem.</span></p> </div> </div> <div > <div > <div > <div > <div > <div > <h2>How did I get AFib?</h2> <p>There are different risk factors of AFib. Your doctor can help identify which ones apply to you.</p> <p>It's also important to note that sometimes your doctor may not know why you developed AFib.</p> </div> </div> <div > <div > <h2>How is AFib related to stroke?</h2> <p>AFib can cause blood clots, which can lead to stroke. An irregular heartbeat can cause blood to pool in the heart, where a blood clot can develop. If a clot forms, it can travel from the heart to the brain and lead to a stroke.</p> </div> </div> <div > <div > <h2>How high is the chance for stroke?</h2> <p>People with AFib are five times more likely to have a stroke, and an AFib-related stroke is typically more severe than other types of strokes.</p> </div> </div> <div > <div > <h2>How do I determine my risk?</h2> <p>You can assess your risk with the CHA<sup >2</sup>DS<sup >2</sup>-VASc calculator. Your CHA<sup >2</sup>DS<sup >2</sup>-VASc score is based on certain factors that can determine your risk for stroke* and whether you need to take an anticoagulant blood thinner. </p> <p>Add points for each condition you have.</p> <p>*Stroke risk increases over time with age and other medical conditions.</p> </div> </div> <div > <div > <h2>What are my treatment options?</h2> <p>Medical treatment options for AFib range from medications, to procedures, to surgery, with the goal of getting your heart back into rhythm. There are a range of medications that can treat AFib, and you may already be taking one.</p> <p>Some medications control your heart rate (like beta blockers), others control your heart rhythm (like sodium or potassium channel blockers), and blood thinners are prescribed to prevent blood from clotting. Your doctor will consider the severity of your AFib and risk of stroke in prescribing the best treatment for you.</p> </div> </div> <div > <div > <h2>How can I protect myself from increased stroke risk?</h2> <p>If your CHA<sup >2</sup>DS<sup >2</sup>-VASc score is 2 or higher, the American Heart Association recommends anticoagulation with a blood thinner. While there are a number of different types of anticoagulants available to help treat AFib, direct oral anticoagulants (DOAC) are one of the newest classes that have some notable advantages when compared to others, including no known dietary restrictions and no routine blood monitoring.</p> <p>The AHA no longer recommends aspirin for AFib-related stroke risk protection, regardless of your risk level.</p> </div> </div> <div > <div > <h2>How can I manage my stroke risk with a DOAC?</h2> <p>XARELTO<sup>®</sup> is a direct-acting oral anticoagulant blood thinner approved by the FDA that significantly reduces the risk of stroke in people with AFib not caused by a heart valve problem.</p> <p>In fact, in a clinical study, more than 96% of people taking XARELTO<sup>®</sup> remained stroke-free.</p> <p>Work with your doctor to determine what's best for you. Consider the severity of your condition and your treatment goals.</p> </div> </div> <div > <div > <h2>What else can I do to support my health?</h2> <p>Heart-healthy activities will not only benefit your AFib condition but also help your overall health. This includes staying active, eating healthy foods low in fat and salt, controlling cholesterol, and maintaining an appropriate weight. </p> </div> </div> </div> </div> <h4>XARELTO<sup>®</sup> offers 24-hour stroke-risk reduction in a once-daily pill.*</h4> <p >*Taken with the evening meal</p> <h4>In fact, in a clinical study, more than 96% of people taking XARELTO<sup>®</sup> remained STROKE-FREE.</h4> </div> <div > <div > <div > <p>If you have AFib, talk to your doctor about all your options.</p> </div> <div > <p>You'll also want to calculate your CHA<sup >2</sup>DS<sup >2</sup>-VASc score so you know what your risk for stroke is, or if it has increased.</p> </div> <div > <p>If you'd like to stay updated on XARELTO<sup>®</sup> news, register here. And remember, you are not alone.</p> </div> <div > <p>There is a community of people with AFib just like you, and you can educate yourself and others by staying informed and spreading the word.</p> </div> </div> </div> </div> <div > <div > <h1>Help Reduce Your Risk of AFib-Related Stroke</h1> Learn More </div> </div> </div> </div> </div> </div><div ><div > <div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div><div > <div > <p>© Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main > </main> <div ><div ><div >WebMD does not endorse any specific product, service, or treatment.</div></div><div ><div > <div > Show More </div> <div > <div ><div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full <a >Prescribing Information</a>, including Boxed Warnings, and <a >Medication Guide</a> for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, level: 1" node_number="1"> <header class="valid" valid="valid" title="valid: True, node: 2, level: 2" node_number="2"/> <div class="valid" valid="valid" title="valid: True, node: 3, level: 2" node_number="3"><div class="valid" valid="valid" title="valid: True, node: 4, level: 3" node_number="4"><div class="valid" valid="valid" title="valid: True, node: 5, level: 4" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, level: 5" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, level: 6" node_number="7"> <h1 class="valid" valid="valid" title="valid: True, node: 8, level: 7" node_number="8"><a class="valid" valid="valid" title="valid: True, node: 9, level: 8" node_number="9">THE TURNING POINT</a></h1> <div class="valid" valid="valid" title="valid: True, node: 10, level: 7" node_number="10"> <ul class="valid" valid="valid" title="valid: True, node: 11, level: 8" node_number="11"> <li class="valid" valid="valid" title="valid: True, node: 12, level: 9" node_number="12"> <a class="valid" valid="valid" title="valid: True, node: 13, level: 10" node_number="13"> AFIB </a> </li> <li class="valid" valid="valid" title="valid: True, node: 14, level: 9" node_number="14"> <a class="valid" valid="valid" title="valid: True, node: 15, level: 10" node_number="15"> DVT/PE </a> </li> <li class="valid" valid="valid" title="valid: True, node: 16, level: 9" node_number="16"> <a class="valid" valid="valid" title="valid: True, node: 17, level: 10" node_number="17"> CAD </a> </li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 18, level: 6" node_number="18"> <div class="valid" valid="valid" title="valid: True, node: 19, level: 7" node_number="19"> <div class="valid" valid="valid" title="valid: True, node: 20, level: 8" node_number="20"> <div class="valid" valid="valid" title="valid: True, node: 21, level: 9" node_number="21"> <p class="valid" valid="valid" title="valid: True, node: 22, level: 10" node_number="22">Living well with AFib starts with self-advocacy</p> <div class="valid" valid="valid" title="valid: True, node: 23, level: 10" node_number="23"> <p class="valid" valid="valid" title="valid: True, node: 24, level: 11" node_number="24">JANET</p> <p class="valid" valid="valid" title="valid: True, node: 25, level: 11" node_number="25">Age 72</p> <p class="valid" valid="valid" title="valid: True, node: 26, level: 11" node_number="26">Diagnosed with AFib in 2014</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 27, level: 8" node_number="27"> <div class="valid" valid="valid" title="valid: True, node: 28, level: 9" node_number="28"> <p class="valid" valid="valid" title="valid: True, node: 29, level: 10" node_number="29">&#8220;This year's our 50th wedding anniversary. We&#8217;re getting the whole family and grandkids and everything together,&#8221; says Janet S., age 72. Janet is celebrating this milestone on a family trip where the whole clan plans to listen to live music and go to amusement parks.</p> <p class="valid" valid="valid" title="valid: True, node: 30, level: 10" node_number="30">In 2014, while getting bloodwork done for an unrelated procedure, Janet was diagnosed with AFib. Luckily, her procedure went well, but her AFib remained since it is a separate condition. At that point, Janet worked with her doctor to understand her diagnosis while also doing her own research.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 31, level: 7" node_number="31"> What is AFib? <p class="valid" valid="valid" title="valid: True, node: 32, level: 8" node_number="32">AFib is an irregular heartbeat that keeps the upper and lower chambers of the heart from working together. This can cause blood to pool in the heart, which can lead to complications like blood clots.</p> <p class="valid" valid="valid" title="valid: True, node: 33, level: 8" node_number="33">Up to 6.1 MILLION Americans are estimated to have atrial fibrillation (AFib), a condition that causes:</p> <div class="valid" valid="valid" title="valid: True, node: 34, level: 8" node_number="34"> <div class="valid" valid="valid" title="valid: True, node: 35, level: 9" node_number="35"> <div class="valid" valid="valid" title="valid: True, node: 36, level: 10" node_number="36"> <p class="valid" valid="valid" title="valid: True, node: 37, level: 11" node_number="37">IRREGULAR HEARTBEAT</p> </div> <div class="valid" valid="valid" title="valid: True, node: 38, level: 10" node_number="38"> <p class="valid" valid="valid" title="valid: True, node: 39, level: 11" node_number="39">HEART PALPITATIONS</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 40, level: 9" node_number="40"> <p class="valid" valid="valid" title="valid: True, node: 41, level: 10" node_number="41">Which lead to:BLOOD POOLING IN THE HEART</p> </div> <div class="valid" valid="valid" title="valid: True, node: 42, level: 9" node_number="42"> <p class="valid" valid="valid" title="valid: True, node: 43, level: 10" node_number="43">Causing:A BLOOD CLOT TO FORM</p> </div> </div> <p class="valid" valid="valid" title="valid: True, node: 44, level: 8" node_number="44">"The causes of AFib are varied," explains Dr. Sanjum Sethi, a cardiologist at Columbia University Medical Center. Other causes include high blood pressure, sleep apnea, excessive consumption of alcohol, being overweight, smoking, diabetes, a family history of AFib, and other heart conditions. </p> <div class="valid" valid="valid" title="valid: True, node: 45, level: 8" node_number="45"> <p class="valid" valid="valid" title="valid: True, node: 46, level: 9" node_number="46">&#8220;If you have a heart valve problem or prior cardiac surgery, those could predispose you to AFib, but most commonly, it&#8217;s a disease of aging&#8230;as we age, the incidence [of AFib] increases quite dramatically."</p> <p class="valid" valid="valid" title="valid: True, node: 47, level: 9" node_number="47">Dr. Sanjum Sethi</p> </div> <div class="valid" valid="valid" title="valid: True, node: 48, level: 8" node_number="48"> Janet's Stroke Risk <p class="valid" valid="valid" title="valid: True, node: 49, level: 9" node_number="49">Janet's doctor explained the CHA<sup class="valid" valid="valid" title="valid: True, node: 50, level: 10" node_number="50">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 51, level: 10" node_number="51">2</sup>-VASc score to her, which is based on certain conditions that determine risk for stroke. &#8220;The scoring system helps us determine what the actual risk is for developing stroke if you have AFib. Not every patient who has AFib is at equal risk for stroke. The CHA<sup class="valid" valid="valid" title="valid: True, node: 52, level: 10" node_number="52">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 53, level: 10" node_number="53">2</sup>-VASc score allows us to determine which patients will benefit the most from receiving anticoagulation," explains Dr. Sethi. Janet has a score of 3 out of 9, with her age, gender, and type II diabetes as the three factors.</p> </div> <p class="valid" valid="valid" title="valid: True, node: 54, level: 8" node_number="54">You can find out your score by using this calculator.</p> <div class="valid" valid="valid" title="valid: True, node: 55, level: 8" node_number="55"> <div class="valid" valid="valid" title="valid: True, node: 56, level: 9" node_number="56"> <p class="valid" valid="valid" title="valid: True, node: 57, level: 10" node_number="57"><span class="valid" valid="valid" title="valid: True, node: 58, level: 11" node_number="58">CHA<sup class="valid" valid="valid" title="valid: True, node: 59, level: 12" node_number="59">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 60, level: 12" node_number="60">2</sup>-VASc: KNOW YOUR RISK</span></p> </div> <div class="valid" valid="valid" title="valid: True, node: 61, level: 9" node_number="61"> <p class="valid" valid="valid" title="valid: True, node: 62, level: 10" node_number="62">Add points below for each condition you have</p> </div> <div class="valid" valid="valid" title="valid: True, node: 63, level: 9" node_number="63"> <div class="valid" valid="valid" title="valid: True, node: 64, level: 10" node_number="64"> <div class="valid" valid="valid" title="valid: True, node: 65, level: 11" node_number="65"> Points </div> <div class="valid" valid="valid" title="valid: True, node: 66, level: 11" node_number="66"> Condition </div> </div> <div class="valid" valid="valid" title="valid: True, node: 67, level: 10" node_number="67"> <div class="valid" valid="valid" title="valid: True, node: 68, level: 11" node_number="68"> Points </div> <div class="valid" valid="valid" title="valid: True, node: 69, level: 11" node_number="69"> Condition </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 70, level: 9" node_number="70"> <div class="valid" valid="valid" title="valid: True, node: 71, level: 10" node_number="71"> <div class="valid" valid="valid" title="valid: True, node: 72, level: 11" node_number="72"> <div class="valid" valid="valid" title="valid: True, node: 73, level: 12" node_number="73"> <h2 class="valid" valid="valid" title="valid: True, node: 74, level: 13" node_number="74">CONGESTIVE HEART FAILURE</h2> <p class="valid" valid="valid" title="valid: True, node: 75, level: 13" node_number="75">Signs/symptoms of heart failure confirmed with test of heart failure</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 76, level: 10" node_number="76"> <div class="valid" valid="valid" title="valid: True, node: 77, level: 11" node_number="77"> <div class="valid" valid="valid" title="valid: True, node: 78, level: 12" node_number="78"> <h2 class="valid" valid="valid" title="valid: True, node: 79, level: 13" node_number="79">HIGH BLOOD PRESSURE</h2> <p class="valid" valid="valid" title="valid: True, node: 80, level: 13" node_number="80">Resting blood pressure &gt;140/90 on at least 2 occasions or on blood pressure meds</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 81, level: 9" node_number="81"> <div class="valid" valid="valid" title="valid: True, node: 82, level: 10" node_number="82"> <div class="valid" valid="valid" title="valid: True, node: 83, level: 11" node_number="83"> <div class="valid" valid="valid" title="valid: True, node: 84, level: 12" node_number="84"> <h2 class="valid" valid="valid" title="valid: True, node: 85, level: 13" node_number="85">AGE 65 TO 74 YEARS</h2> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 86, level: 10" node_number="86"> <div class="valid" valid="valid" title="valid: True, node: 87, level: 11" node_number="87"> <div class="valid" valid="valid" title="valid: True, node: 88, level: 12" node_number="88"> <h2 class="valid" valid="valid" title="valid: True, node: 89, level: 13" node_number="89">DIABETES MELLITUS</h2> <p class="valid" valid="valid" title="valid: True, node: 90, level: 13" node_number="90">Fasting blood sugar &gt;125 mg/dL or on medications or insulin</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 91, level: 9" node_number="91"> <div class="valid" valid="valid" title="valid: True, node: 92, level: 10" node_number="92"> <div class="valid" valid="valid" title="valid: True, node: 93, level: 11" node_number="93"> <div class="valid" valid="valid" title="valid: True, node: 94, level: 12" node_number="94"> <h2 class="valid" valid="valid" title="valid: True, node: 95, level: 13" node_number="95">STROKE</h2> <p class="valid" valid="valid" title="valid: True, node: 96, level: 13" node_number="96">Includes any history of stroke</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 97, level: 10" node_number="97"> <div class="valid" valid="valid" title="valid: True, node: 98, level: 11" node_number="98"> <div class="valid" valid="valid" title="valid: True, node: 99, level: 12" node_number="99"> <h2 class="valid" valid="valid" title="valid: True, node: 100, level: 13" node_number="100">VASCULAR DISEASE</h2> <p class="valid" valid="valid" title="valid: True, node: 101, level: 13" node_number="101">Prior heart attack, peripheral artery disease, or aortic plaque</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 102, level: 9" node_number="102"> <div class="valid" valid="valid" title="valid: True, node: 103, level: 10" node_number="103"> <div class="valid" valid="valid" title="valid: True, node: 104, level: 11" node_number="104"> <div class="valid" valid="valid" title="valid: True, node: 105, level: 12" node_number="105"> <h2 class="valid" valid="valid" title="valid: True, node: 106, level: 13" node_number="106">AGE 75 YEARS OR OLDER</h2> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 107, level: 10" node_number="107"> <div class="valid" valid="valid" title="valid: True, node: 108, level: 11" node_number="108"> <div class="valid" valid="valid" title="valid: True, node: 109, level: 12" node_number="109"> <h2 class="valid" valid="valid" title="valid: True, node: 110, level: 13" node_number="110">SEX CATEGORY (FEMALE)</h2> <p class="valid" valid="valid" title="valid: True, node: 111, level: 13" node_number="111">Female gender means a higher risk</p> </div> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 112, level: 8" node_number="112"> <div class="valid" valid="valid" title="valid: True, node: 113, level: 9" node_number="113"><p class="valid" valid="valid" title="valid: True, node: 114, level: 10" node_number="114">The American Heart Association recommends anticoagulation with a blood thinner for a score of 2 OR HIGHER.</p></div> </div> <div class="valid" valid="valid" title="valid: True, node: 115, level: 8" node_number="115"> <div class="valid" valid="valid" title="valid: True, node: 116, level: 9" node_number="116"><p class="valid" valid="valid" title="valid: True, node: 117, level: 10" node_number="117">REMINDER: Even if you are taking medicine to treat your AFib and not experiencing symptoms, YOUR STROKE RISK WILL CONTINUE TO INCREASE OVER TIME.</p></div> </div> <div class="valid" valid="valid" title="valid: True, node: 118, level: 8" node_number="118"> <div class="valid" valid="valid" title="valid: True, node: 119, level: 9" node_number="119"><p class="valid" valid="valid" title="valid: True, node: 120, level: 10" node_number="120">YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> <div class="valid" valid="valid" title="valid: True, node: 121, level: 8" node_number="121"> Symptoms <p class="valid" valid="valid" title="valid: True, node: 122, level: 9" node_number="122">Common symptoms of AFib are a rapid and irregular heartbeat, heart palpitations, chest pain or pressure, dizziness, fainting, shortness of breath, or fatigue&#8212;but some people experience no symptoms at all. When Janet was first diagnosed, she would experience short periods of heart racing but was lucky that her symptoms never reached extreme levels. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 123, level: 8" node_number="123"> <p class="valid" valid="valid" title="valid: True, node: 124, level: 9" node_number="124">&#8220;AFib is tricky in the sense that some people are very symptomatic, and some people have no symptoms at all. AFib is an electrical problem of the heart where the top chamber is beating a lot faster than the bottom chamber. The body is often able to compensate for the electrical problem, so you may experience no symptoms at all." </p> <p class="valid" valid="valid" title="valid: True, node: 125, level: 9" node_number="125">Dr. Sanjum Sethi</p> </div> <p class="valid" valid="valid" title="valid: True, node: 126, level: 8" node_number="126">Because of all her research, Janet was aware that AFib can cause blood clots, which can lead to stroke, so she made the decision with her doctor to start an aspirin regimen to lower her risks.</p> <div class="valid" valid="valid" title="valid: True, node: 127, level: 8" node_number="127"> People with AFib are5 TIMES MORE LIKELY to have a stroke </div> <p class="valid" valid="valid" title="valid: True, node: 128, level: 8" node_number="128">Stroke is a serious consequence of AFib. Complications from AFib, such as heart palpitations and irregular heartbeats, can cause blood to pool in the heart, where a clot can develop. </p> <h3 class="valid" valid="valid" title="valid: True, node: 129, level: 8" node_number="129">Why blood clots matter:</h3> <div class="valid" valid="valid" title="valid: True, node: 130, level: 8" node_number="130"> <div class="valid" valid="valid" title="valid: True, node: 131, level: 9" node_number="131"> <h3 class="valid" valid="valid" title="valid: True, node: 132, level: 10" node_number="132">CLOTS CAN TRAVEL FROMTHE HEART TO THE BRAIN</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 133, level: 9" node_number="133"> <h3 class="valid" valid="valid" title="valid: True, node: 134, level: 10" node_number="134">CREATING BLOCKAGES</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 135, level: 9" node_number="135"> <h3 class="valid" valid="valid" title="valid: True, node: 136, level: 10" node_number="136">WHICH CAN CAUSE A STROKE</h3> </div> </div> <p class="valid" valid="valid" title="valid: True, node: 137, level: 8" node_number="137">Even if you are treating your AFib and feeling fine, your stroke risk continues to increase over time. That&#8217;s why it&#8217;s important to periodically review your <span class="valid" valid="valid" title="valid: True, node: 138, level: 9" node_number="138">CHA<sup class="valid" valid="valid" title="valid: True, node: 139, level: 10" node_number="139">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 140, level: 10" node_number="140">2</sup>-VASc score with your doctor.</span></p> </div> <div class="valid" valid="valid" title="valid: True, node: 141, level: 7" node_number="141"> <div class="valid" valid="valid" title="valid: True, node: 142, level: 8" node_number="142"> <h3 class="valid" valid="valid" title="valid: True, node: 143, level: 9" node_number="143">Janet's Turning Point</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 144, level: 8" node_number="144"> <p class="valid" valid="valid" title="valid: True, node: 145, level: 9" node_number="145">After initially treating AFib with aspirin, Janet saw a doctor who recommended a blood thinner called XARELTO<sup class="valid" valid="valid" title="valid: True, node: 146, level: 10" node_number="146">&#174;</sup>. While aspirin was once considered a treatment for those at low risk for stroke, the AHA no longer recommends aspirin for the treatment of AFib, regardless of risk level. As her own best advocate, Janet stays up-to-date on the benefits and risks of taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 147, level: 10" node_number="147">&#174;</sup>. Her husband also plays a large role in her health.</p> <div class="valid" valid="valid" title="valid: True, node: 148, level: 9" node_number="148"> <p class="valid" valid="valid" title="valid: True, node: 149, level: 10" node_number="149">&#8220;He really wants me to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 150, level: 11" node_number="150">&#174;</sup> because he doesn't want me to have a stroke either. We support each other. He'll remind me to take my meds after dinner."</p> <p class="valid" valid="valid" title="valid: True, node: 151, level: 10" node_number="151">Janet</p> </div> <p class="valid" valid="valid" title="valid: True, node: 152, level: 9" node_number="152">With 6 children and 15 grandchildren, there's no shortage of people who are counting on Janet to stay healthy. &#8220;I know how devastating [strokes] can be and I did think about my children and grandchildren and my husband&#8230;I thought if I could avoid having one, that would be good&#8212;live a longer life without impairment, that would be great. I know some people that've had strokes, and it's really tough," says Janet. Along with taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 153, level: 10" node_number="153">&#174;</sup>, Janet now exercises more. She belongs to a local gym and goes on a vigorous walk once a week. This has also allowed her to take advantage of her city's metro park system. </p> <p class="valid" valid="valid" title="valid: True, node: 154, level: 9" node_number="154">Janet is proof that working with your doctor is integral to managing AFib-related stroke and blood clots. A combination of her own research and conversations with various doctors has led her to a plan that includes once-daily XARELTO<sup class="valid" valid="valid" title="valid: True, node: 155, level: 10" node_number="155">&#174;</sup> to lower her risk for stroke. <span class="valid" valid="valid" title="valid: True, node: 156, level: 10" node_number="156">Because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 157, level: 11" node_number="157">&#174;</sup> is a blood thinner, it helps prevent or reduce blood clotting, which significantly reduces the risk of stroke in people with AFib not caused by a heart valve problem.</span></p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 158, level: 7" node_number="158"> <div class="valid" valid="valid" title="valid: True, node: 159, level: 8" node_number="159"> <div class="valid" valid="valid" title="valid: True, node: 160, level: 9" node_number="160"> <div class="valid" valid="valid" title="valid: True, node: 161, level: 10" node_number="161"> <div class="valid" valid="valid" title="valid: True, node: 162, level: 11" node_number="162"> <div class="valid" valid="valid" title="valid: True, node: 163, level: 12" node_number="163"> <h2 class="valid" valid="valid" title="valid: True, node: 164, level: 13" node_number="164">How did I get AFib?</h2> <p class="valid" valid="valid" title="valid: True, node: 165, level: 13" node_number="165">There are different risk factors of AFib. Your doctor can help identify which ones apply to you.</p> <p class="valid" valid="valid" title="valid: True, node: 166, level: 13" node_number="166">It's also important to note that sometimes your doctor may not know why you developed AFib.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 167, level: 11" node_number="167"> <div class="valid" valid="valid" title="valid: True, node: 168, level: 12" node_number="168"> <h2 class="valid" valid="valid" title="valid: True, node: 169, level: 13" node_number="169">How is AFib related to stroke?</h2> <p class="valid" valid="valid" title="valid: True, node: 170, level: 13" node_number="170">AFib can cause blood clots, which can lead to stroke. An irregular heartbeat can cause blood to pool in the heart, where a blood clot can develop. If a clot forms, it can travel from the heart to the brain and lead to a stroke.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 171, level: 11" node_number="171"> <div class="valid" valid="valid" title="valid: True, node: 172, level: 12" node_number="172"> <h2 class="valid" valid="valid" title="valid: True, node: 173, level: 13" node_number="173">How high is the chance for stroke?</h2> <p class="valid" valid="valid" title="valid: True, node: 174, level: 13" node_number="174">People with AFib are five times more likely to have a stroke, and an AFib-related stroke is typically more severe than other types of strokes.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 175, level: 11" node_number="175"> <div class="valid" valid="valid" title="valid: True, node: 176, level: 12" node_number="176"> <h2 class="valid" valid="valid" title="valid: True, node: 177, level: 13" node_number="177">How do I determine my risk?</h2> <p class="valid" valid="valid" title="valid: True, node: 178, level: 13" node_number="178">You can assess your risk with the CHA<sup class="valid" valid="valid" title="valid: True, node: 179, level: 14" node_number="179">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 180, level: 14" node_number="180">2</sup>-VASc calculator. Your CHA<sup class="valid" valid="valid" title="valid: True, node: 181, level: 14" node_number="181">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 182, level: 14" node_number="182">2</sup>-VASc score is based on certain factors that can determine your risk for stroke* and whether you need to take an anticoagulant blood thinner. </p> <p class="valid" valid="valid" title="valid: True, node: 183, level: 13" node_number="183">Add points for each condition you have.</p> <p class="valid" valid="valid" title="valid: True, node: 184, level: 13" node_number="184">*Stroke risk increases over time with age and other medical conditions.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 185, level: 11" node_number="185"> <div class="valid" valid="valid" title="valid: True, node: 186, level: 12" node_number="186"> <h2 class="valid" valid="valid" title="valid: True, node: 187, level: 13" node_number="187">What are my treatment options?</h2> <p class="valid" valid="valid" title="valid: True, node: 188, level: 13" node_number="188">Medical treatment options for AFib range from medications, to procedures, to surgery, with the goal of getting your heart back into rhythm. There are a range of medications that can treat AFib, and you may already be taking one.</p> <p class="valid" valid="valid" title="valid: True, node: 189, level: 13" node_number="189">Some medications control your heart rate (like beta blockers), others control your heart rhythm (like sodium or potassium channel blockers), and blood thinners are prescribed to prevent blood from clotting. Your doctor will consider the severity of your AFib and risk of stroke in prescribing the best treatment for you.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 190, level: 11" node_number="190"> <div class="valid" valid="valid" title="valid: True, node: 191, level: 12" node_number="191"> <h2 class="valid" valid="valid" title="valid: True, node: 192, level: 13" node_number="192">How can I protect myself from increased stroke risk?</h2> <p class="valid" valid="valid" title="valid: True, node: 193, level: 13" node_number="193">If your CHA<sup class="valid" valid="valid" title="valid: True, node: 194, level: 14" node_number="194">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 195, level: 14" node_number="195">2</sup>-VASc score is 2 or higher, the American Heart Association recommends anticoagulation with a blood thinner. While there are a number of different types of anticoagulants available to help treat AFib, direct oral anticoagulants (DOAC) are one of the newest classes that have some notable advantages when compared to others, including no known dietary restrictions and no routine blood monitoring.</p> <p class="valid" valid="valid" title="valid: True, node: 196, level: 13" node_number="196">The AHA no longer recommends aspirin for AFib-related stroke risk protection, regardless of your risk level.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 197, level: 11" node_number="197"> <div class="valid" valid="valid" title="valid: True, node: 198, level: 12" node_number="198"> <h2 class="valid" valid="valid" title="valid: True, node: 199, level: 13" node_number="199">How can I manage my stroke risk with a DOAC?</h2> <p class="valid" valid="valid" title="valid: True, node: 200, level: 13" node_number="200">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 201, level: 14" node_number="201">&#174;</sup> is a direct-acting oral anticoagulant blood thinner approved by the FDA that significantly reduces the risk of stroke in people with AFib not caused by a heart valve problem.</p> <p class="valid" valid="valid" title="valid: True, node: 202, level: 13" node_number="202">In fact, in a clinical study, more than 96% of people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 203, level: 14" node_number="203">&#174;</sup> remained stroke-free.</p> <p class="valid" valid="valid" title="valid: True, node: 204, level: 13" node_number="204">Work with your doctor to determine what's best for you. Consider the severity of your condition and your treatment goals.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 205, level: 11" node_number="205"> <div class="valid" valid="valid" title="valid: True, node: 206, level: 12" node_number="206"> <h2 class="valid" valid="valid" title="valid: True, node: 207, level: 13" node_number="207">What else can I do to support my health?</h2> <p class="valid" valid="valid" title="valid: True, node: 208, level: 13" node_number="208">Heart-healthy activities will not only benefit your AFib condition but also help your overall health. This includes staying active, eating healthy foods low in fat and salt, controlling cholesterol, and maintaining an appropriate weight. </p> </div> </div> </div> </div> <h4 class="valid" valid="valid" title="valid: True, node: 209, level: 9" node_number="209">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 210, level: 10" node_number="210">&#174;</sup> offers 24-hour stroke-risk reduction in a once-daily pill.*</h4> <p class="valid" valid="valid" title="valid: True, node: 211, level: 9" node_number="211">*Taken with the evening meal</p> <h4 class="valid" valid="valid" title="valid: True, node: 212, level: 9" node_number="212">In fact, in a clinical study, more than 96% of people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 213, level: 10" node_number="213">&#174;</sup> remained STROKE-FREE.</h4> </div> <div class="valid" valid="valid" title="valid: True, node: 214, level: 8" node_number="214"> <div class="valid" valid="valid" title="valid: True, node: 215, level: 9" node_number="215"> <div class="valid" valid="valid" title="valid: True, node: 216, level: 10" node_number="216"> <p class="valid" valid="valid" title="valid: True, node: 217, level: 11" node_number="217">If you have AFib, talk to your doctor about all your options.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 218, level: 10" node_number="218"> <p class="valid" valid="valid" title="valid: True, node: 219, level: 11" node_number="219">You'll also want to calculate your CHA<sup class="valid" valid="valid" title="valid: True, node: 220, level: 12" node_number="220">2</sup>DS<sup class="valid" valid="valid" title="valid: True, node: 221, level: 12" node_number="221">2</sup>-VASc score so you know what your risk for stroke is, or if it has increased.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 222, level: 10" node_number="222"> <p class="valid" valid="valid" title="valid: True, node: 223, level: 11" node_number="223">If you'd like to stay updated on XARELTO<sup class="valid" valid="valid" title="valid: True, node: 224, level: 12" node_number="224">&#174;</sup> news, register here. And remember, you are not alone.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 225, level: 10" node_number="225"> <p class="valid" valid="valid" title="valid: True, node: 226, level: 11" node_number="226">There is a community of people with AFib just like you, and you can educate yourself and others by staying informed and spreading the word.</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 227, level: 7" node_number="227"> <div class="valid" valid="valid" title="valid: True, node: 228, level: 8" node_number="228"> <h1 class="valid" valid="valid" title="valid: True, node: 229, level: 9" node_number="229">Help Reduce Your Risk of AFib-Related Stroke</h1> Learn More </div> </div> </div> </div> </div> </div><div class="valid" valid="valid" title="valid: True, node: 230, level: 3" node_number="230"><div class="valid" valid="valid" title="valid: True, node: 231, level: 4" node_number="231"> <div class="valid" valid="valid" title="valid: True, node: 232, level: 5" node_number="232"> <div class="valid" valid="valid" title="valid: True, node: 233, level: 6" node_number="233"> <div class="valid" valid="valid" title="valid: True, node: 234, level: 7" node_number="234"> <div class="valid" valid="valid" title="valid: True, node: 235, level: 8" node_number="235"> <div class="valid" valid="valid" title="valid: True, node: 236, level: 9" node_number="236"> <div class="valid" valid="valid" title="valid: True, node: 237, level: 10" node_number="237"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 238, level: 11" node_number="238">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 239, level: 10" node_number="239"> <p class="valid" valid="valid" title="valid: True, node: 240, level: 11" node_number="240">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 241, level: 12" node_number="241">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 242, level: 11" node_number="242"> <li class="valid" valid="valid" title="valid: True, node: 243, level: 12" node_number="243"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 244, level: 12" node_number="244"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 245, level: 12" node_number="245"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 246, level: 11" node_number="246">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 247, level: 12" node_number="247">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 248, level: 11" node_number="248"> <li class="valid" valid="valid" title="valid: True, node: 249, level: 12" node_number="249"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 250, level: 11" node_number="250">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 251, level: 12" node_number="251">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 252, level: 9" node_number="252"> <div class="valid" valid="valid" title="valid: True, node: 253, level: 10" node_number="253">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 254, level: 11" node_number="254">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 255, level: 10" node_number="255"> <p class="valid" valid="valid" title="valid: True, node: 256, level: 11" node_number="256">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 257, level: 12" node_number="257">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 258, level: 11" node_number="258"> <li class="valid" valid="valid" title="valid: True, node: 259, level: 12" node_number="259">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 260, level: 11" node_number="260">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 261, level: 12" node_number="261">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 262, level: 9" node_number="262"> <div class="valid" valid="valid" title="valid: True, node: 263, level: 10" node_number="263">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 264, level: 11" node_number="264">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 265, level: 10" node_number="265"> <p class="valid" valid="valid" title="valid: True, node: 266, level: 11" node_number="266">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 267, level: 12" node_number="267">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 268, level: 11" node_number="268"> <li class="valid" valid="valid" title="valid: True, node: 269, level: 12" node_number="269">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 270, level: 12" node_number="270">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 271, level: 11" node_number="271">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 272, level: 12" node_number="272">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 273, level: 9" node_number="273"> <div class="valid" valid="valid" title="valid: True, node: 274, level: 10" node_number="274">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 275, level: 11" node_number="275">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 276, level: 10" node_number="276"> <p class="valid" valid="valid" title="valid: True, node: 277, level: 11" node_number="277">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 278, level: 12" node_number="278">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 279, level: 11" node_number="279"> <li class="valid" valid="valid" title="valid: True, node: 280, level: 12" node_number="280">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 281, level: 11" node_number="281">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 282, level: 12" node_number="282">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 283, level: 8" node_number="283"> <h3 class="valid" valid="valid" title="valid: True, node: 284, level: 9" node_number="284">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 285, level: 9" node_number="285">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 286, level: 10" node_number="286">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 287, level: 9" node_number="287"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 288, level: 10" node_number="288">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 289, level: 9" node_number="289"> <li class="valid" valid="valid" title="valid: True, node: 290, level: 10" node_number="290"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 291, level: 11" node_number="291">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 292, level: 11" node_number="292">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 293, level: 11" node_number="293">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 294, level: 10" node_number="294"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 295, level: 11" node_number="295">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 296, level: 11" node_number="296">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 297, level: 11" node_number="297">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 298, level: 10" node_number="298"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 299, level: 11" node_number="299">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 300, level: 11" node_number="300">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 301, level: 11" node_number="301">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 302, level: 11" node_number="302">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 303, level: 9" node_number="303"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 304, level: 10" node_number="304">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 305, level: 9" node_number="305"> <li class="valid" valid="valid" title="valid: True, node: 306, level: 10" node_number="306">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 307, level: 10" node_number="307">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 308, level: 10" node_number="308">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 309, level: 11" node_number="309">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 310, level: 11" node_number="310">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 311, level: 10" node_number="311">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 312, level: 10" node_number="312">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 313, level: 11" node_number="313">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 314, level: 10" node_number="314">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 315, level: 10" node_number="315">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 316, level: 9" node_number="316"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 317, level: 9" node_number="317"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 318, level: 9" node_number="318"> <li class="valid" valid="valid" title="valid: True, node: 319, level: 10" node_number="319">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 320, level: 9" node_number="320"> <li class="valid" valid="valid" title="valid: True, node: 321, level: 10" node_number="321">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 322, level: 10" node_number="322">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 323, level: 10" node_number="323">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 324, level: 9" node_number="324"> <li class="valid" valid="valid" title="valid: True, node: 325, level: 10" node_number="325">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 326, level: 10" node_number="326">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 327, level: 10" node_number="327">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 328, level: 10" node_number="328">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 329, level: 10" node_number="329">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 330, level: 10" node_number="330">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 331, level: 10" node_number="331">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 332, level: 9" node_number="332"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 333, level: 10" node_number="333">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 334, level: 10" node_number="334"> <li class="valid" valid="valid" title="valid: True, node: 335, level: 11" node_number="335"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 336, level: 11" node_number="336"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 337, level: 11" node_number="337"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 338, level: 11" node_number="338"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 339, level: 9" node_number="339"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 340, level: 10" node_number="340">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 341, level: 9" node_number="341"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 342, level: 10" node_number="342">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 343, level: 9" node_number="343"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 344, level: 10" node_number="344">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 345, level: 9" node_number="345"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 346, level: 10" node_number="346">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 347, level: 9" node_number="347"> <li class="valid" valid="valid" title="valid: True, node: 348, level: 10" node_number="348"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 349, level: 11" node_number="349">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 350, level: 10" node_number="350"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 351, level: 11" node_number="351">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 352, level: 9" node_number="352"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 353, level: 10" node_number="353">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 354, level: 9" node_number="354"> <li class="valid" valid="valid" title="valid: True, node: 355, level: 10" node_number="355"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 356, level: 10" node_number="356"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 357, level: 10" node_number="357"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 358, level: 10" node_number="358"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 359, level: 11" node_number="359">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 360, level: 11" node_number="360"> <li class="valid" valid="valid" title="valid: True, node: 361, level: 12" node_number="361"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 362, level: 13" node_number="362">&#174;</sup>. Taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 363, level: 13" node_number="363">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 364, level: 12" node_number="364"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 365, level: 13" node_number="365">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 366, level: 13" node_number="366">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 367, level: 10" node_number="367"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 368, level: 11" node_number="368">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 369, level: 11" node_number="369">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 370, level: 9" node_number="370"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 371, level: 10" node_number="371">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 372, level: 10" node_number="372">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 373, level: 9" node_number="373"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 374, level: 10" node_number="374">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 375, level: 9" node_number="375"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 376, level: 10" node_number="376">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 377, level: 10" node_number="377">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 378, level: 9" node_number="378"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 379, level: 10" node_number="379">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 380, level: 9" node_number="380"> <li class="valid" valid="valid" title="valid: True, node: 381, level: 10" node_number="381"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 382, level: 11" node_number="382">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 383, level: 10" node_number="383"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 384, level: 11" node_number="384">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 385, level: 10" node_number="385"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 386, level: 11" node_number="386">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 387, level: 10" node_number="387"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 388, level: 11" node_number="388">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 389, level: 11" node_number="389">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 390, level: 11" node_number="390">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 391, level: 10" node_number="391"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 392, level: 11" node_number="392">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 393, level: 11" node_number="393">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 394, level: 11" node_number="394">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 395, level: 10" node_number="395"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 396, level: 11" node_number="396">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 397, level: 11" node_number="397">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 398, level: 10" node_number="398"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 399, level: 11" node_number="399">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 400, level: 11" node_number="400">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 401, level: 11" node_number="401">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 402, level: 10" node_number="402"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 403, level: 11" node_number="403">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 404, level: 9" node_number="404"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 405, level: 10" node_number="405">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 406, level: 9" node_number="406"> <ul class="valid" valid="valid" title="valid: True, node: 407, level: 10" node_number="407"> <li class="valid" valid="valid" title="valid: True, node: 408, level: 11" node_number="408"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 409, level: 12" node_number="409"> <li class="valid" valid="valid" title="valid: True, node: 410, level: 13" node_number="410"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 411, level: 14" node_number="411">&#174;</sup> 1 time a day with your evening meal. </li> <li class="valid" valid="valid" title="valid: True, node: 412, level: 13" node_number="412"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 413, level: 14" node_number="413">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 414, level: 11" node_number="414"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 415, level: 12" node_number="415"> <li class="valid" valid="valid" title="valid: True, node: 416, level: 13" node_number="416"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 417, level: 14" node_number="417">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 418, level: 13" node_number="418"> For the 10-mg dose, XARELTO<sup class="valid" valid="valid" title="valid: True, node: 419, level: 14" node_number="419">&#174;</sup> may be taken with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 420, level: 13" node_number="420"> For the 15-mg and 20-mg doses, take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 421, level: 14" node_number="421">&#174;</sup> with food at the same time each day. </li> <li class="valid" valid="valid" title="valid: True, node: 422, level: 13" node_number="422"> If you miss a dose: <ul class="valid" valid="valid" title="valid: True, node: 423, level: 14" node_number="423"> <li title="valid: False, node: 424, level: 15" node_number="424"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 425, level: 16" node_number="425">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 426, level: 16" node_number="426">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 427, level: 16" node_number="427">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 428, level: 15" node_number="428"> If you take XARELTO<sup title="valid: False, node: 429, level: 16" node_number="429">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 430, level: 16" node_number="430">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 431, level: 11" node_number="431"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 432, level: 12" node_number="432"> <li class="valid" valid="valid" title="valid: True, node: 433, level: 13" node_number="433"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 434, level: 14" node_number="434">&#174;</sup> 1 time a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 435, level: 13" node_number="435"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 436, level: 14" node_number="436">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 437, level: 11" node_number="437"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 438, level: 12" node_number="438"> <li class="valid" valid="valid" title="valid: True, node: 439, level: 13" node_number="439"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 440, level: 14" node_number="440">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 441, level: 13" node_number="441"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 442, level: 14" node_number="442">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 443, level: 11" node_number="443"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 444, level: 12" node_number="444"> <li class="valid" valid="valid" title="valid: True, node: 445, level: 13" node_number="445"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 446, level: 14" node_number="446">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 447, level: 13" node_number="447"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 448, level: 14" node_number="448">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li class="valid" valid="valid" title="valid: True, node: 449, level: 13" node_number="449"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 450, level: 9" node_number="450"> <p class="valid" valid="valid" title="valid: True, node: 451, level: 10" node_number="451"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 452, level: 11" node_number="452">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 453, level: 12" node_number="453">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 454, level: 10" node_number="454"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 455, level: 11" node_number="455">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 456, level: 10" node_number="456"> <li class="valid" valid="valid" title="valid: True, node: 457, level: 11" node_number="457"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 458, level: 12" node_number="458">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 459, level: 10" node_number="459"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 460, level: 11" node_number="460">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 461, level: 10" node_number="461"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 462, level: 10" node_number="462"> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 463, level: 11" node_number="463">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 464, level: 10" node_number="464"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 465, level: 10" node_number="465"> cp-53637v6 </p> </div> </div> </div> </div> </div></div><div class="valid" valid="valid" title="valid: True, node: 466, level: 4" node_number="466"> <div class="valid" valid="valid" title="valid: True, node: 467, level: 5" node_number="467"> <p class="valid" valid="valid" title="valid: True, node: 468, level: 6" node_number="468">&#169; Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 469, level: 2" node_number="469"> </main> <div class="valid" valid="valid" title="valid: True, node: 470, level: 2" node_number="470"><div class="valid" valid="valid" title="valid: True, node: 471, level: 3" node_number="471"><div class="valid" valid="valid" title="valid: True, node: 472, level: 4" node_number="472">WebMD does not endorse any specific product, service, or treatment.</div></div><div class="valid" valid="valid" title="valid: True, node: 473, level: 3" node_number="473"><div class="valid" valid="valid" title="valid: True, node: 474, level: 4" node_number="474"> <div class="valid" valid="valid" title="valid: True, node: 475, level: 5" node_number="475"> Show More </div> <div class="valid" valid="valid" title="valid: True, node: 476, level: 5" node_number="476"> <div class="valid" valid="valid" title="valid: True, node: 477, level: 6" node_number="477"><div class="valid" valid="valid" title="valid: True, node: 478, level: 7" node_number="478"> <div class="valid" valid="valid" title="valid: True, node: 479, level: 8" node_number="479"> <div class="valid" valid="valid" title="valid: True, node: 480, level: 9" node_number="480"> <div class="valid" valid="valid" title="valid: True, node: 481, level: 10" node_number="481"> <div class="valid" valid="valid" title="valid: True, node: 482, level: 11" node_number="482"> <div class="valid" valid="valid" title="valid: True, node: 483, level: 12" node_number="483"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 484, level: 13" node_number="484">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 485, level: 12" node_number="485"> <p class="valid" valid="valid" title="valid: True, node: 486, level: 13" node_number="486">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 487, level: 14" node_number="487">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 488, level: 13" node_number="488"> <li class="valid" valid="valid" title="valid: True, node: 489, level: 14" node_number="489"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 490, level: 14" node_number="490"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 491, level: 14" node_number="491"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 492, level: 13" node_number="492">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 493, level: 14" node_number="493">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 494, level: 13" node_number="494"> <li class="valid" valid="valid" title="valid: True, node: 495, level: 14" node_number="495"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 496, level: 13" node_number="496">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 497, level: 14" node_number="497">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 498, level: 11" node_number="498"> <div class="valid" valid="valid" title="valid: True, node: 499, level: 12" node_number="499">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 500, level: 13" node_number="500">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 501, level: 12" node_number="501"> <p class="valid" valid="valid" title="valid: True, node: 502, level: 13" node_number="502">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 503, level: 14" node_number="503">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 504, level: 13" node_number="504"> <li class="valid" valid="valid" title="valid: True, node: 505, level: 14" node_number="505">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 506, level: 13" node_number="506">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 507, level: 14" node_number="507">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 508, level: 11" node_number="508"> <div class="valid" valid="valid" title="valid: True, node: 509, level: 12" node_number="509">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 510, level: 13" node_number="510">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 511, level: 12" node_number="511"> <p class="valid" valid="valid" title="valid: True, node: 512, level: 13" node_number="512">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 513, level: 14" node_number="513">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 514, level: 13" node_number="514"> <li class="valid" valid="valid" title="valid: True, node: 515, level: 14" node_number="515">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 516, level: 14" node_number="516">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 517, level: 13" node_number="517">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 518, level: 14" node_number="518">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 519, level: 11" node_number="519"> <div class="valid" valid="valid" title="valid: True, node: 520, level: 12" node_number="520">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 521, level: 13" node_number="521">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 522, level: 12" node_number="522"> <p class="valid" valid="valid" title="valid: True, node: 523, level: 13" node_number="523">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 524, level: 14" node_number="524">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 525, level: 13" node_number="525"> <li class="valid" valid="valid" title="valid: True, node: 526, level: 14" node_number="526">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 527, level: 13" node_number="527">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 528, level: 14" node_number="528">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 529, level: 10" node_number="529"> <h3 class="valid" valid="valid" title="valid: True, node: 530, level: 11" node_number="530">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 531, level: 11" node_number="531">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 532, level: 12" node_number="532">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 533, level: 11" node_number="533"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 534, level: 12" node_number="534">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 535, level: 11" node_number="535"> <li class="valid" valid="valid" title="valid: True, node: 536, level: 12" node_number="536"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 537, level: 13" node_number="537">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 538, level: 13" node_number="538">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 539, level: 13" node_number="539">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 540, level: 12" node_number="540"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 541, level: 13" node_number="541">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 542, level: 13" node_number="542">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 543, level: 13" node_number="543">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 544, level: 12" node_number="544"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 545, level: 13" node_number="545">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 546, level: 13" node_number="546">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 547, level: 13" node_number="547">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 548, level: 13" node_number="548">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 549, level: 11" node_number="549"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 550, level: 12" node_number="550">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 551, level: 11" node_number="551"> <li class="valid" valid="valid" title="valid: True, node: 552, level: 12" node_number="552">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 553, level: 12" node_number="553">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 554, level: 12" node_number="554">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 555, level: 13" node_number="555">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 556, level: 13" node_number="556">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 557, level: 12" node_number="557">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 558, level: 12" node_number="558">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 559, level: 13" node_number="559">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 560, level: 12" node_number="560">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 561, level: 12" node_number="561">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 562, level: 11" node_number="562"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 563, level: 11" node_number="563"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 564, level: 11" node_number="564"> <li class="valid" valid="valid" title="valid: True, node: 565, level: 12" node_number="565">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 566, level: 11" node_number="566"> <li class="valid" valid="valid" title="valid: True, node: 567, level: 12" node_number="567">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 568, level: 12" node_number="568">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 569, level: 12" node_number="569">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 570, level: 11" node_number="570"> <li class="valid" valid="valid" title="valid: True, node: 571, level: 12" node_number="571">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 572, level: 12" node_number="572">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 573, level: 12" node_number="573">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 574, level: 12" node_number="574">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 575, level: 12" node_number="575">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 576, level: 12" node_number="576">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 577, level: 12" node_number="577">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 578, level: 11" node_number="578"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 579, level: 12" node_number="579">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 580, level: 12" node_number="580"> <li class="valid" valid="valid" title="valid: True, node: 581, level: 13" node_number="581"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 582, level: 13" node_number="582"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 583, level: 13" node_number="583"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 584, level: 13" node_number="584"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 585, level: 11" node_number="585"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 586, level: 12" node_number="586">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 587, level: 11" node_number="587"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 588, level: 12" node_number="588">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 589, level: 11" node_number="589"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 590, level: 12" node_number="590">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 591, level: 11" node_number="591"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 592, level: 12" node_number="592">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 593, level: 11" node_number="593"> <li class="valid" valid="valid" title="valid: True, node: 594, level: 12" node_number="594"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 595, level: 13" node_number="595">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 596, level: 12" node_number="596"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 597, level: 13" node_number="597">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 598, level: 11" node_number="598"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 599, level: 12" node_number="599">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 600, level: 11" node_number="600"> <li class="valid" valid="valid" title="valid: True, node: 601, level: 12" node_number="601"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 602, level: 12" node_number="602"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 603, level: 12" node_number="603"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 604, level: 12" node_number="604"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 605, level: 13" node_number="605">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 606, level: 13" node_number="606"> <li class="valid" valid="valid" title="valid: True, node: 607, level: 14" node_number="607"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup title="valid: False, node: 608, level: 15" node_number="608">&#174;</sup>. Taking XARELTO<sup title="valid: False, node: 609, level: 15" node_number="609">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 610, level: 14" node_number="610"> If you take XARELTO<sup title="valid: False, node: 611, level: 15" node_number="611">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup title="valid: False, node: 612, level: 15" node_number="612">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 613, level: 12" node_number="613"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 614, level: 13" node_number="614">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 615, level: 13" node_number="615">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 616, level: 11" node_number="616"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 617, level: 12" node_number="617">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 618, level: 12" node_number="618">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 619, level: 11" node_number="619"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 620, level: 12" node_number="620">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 621, level: 11" node_number="621"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 622, level: 12" node_number="622">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 623, level: 12" node_number="623">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 624, level: 11" node_number="624"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 625, level: 12" node_number="625">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 626, level: 11" node_number="626"> <li class="valid" valid="valid" title="valid: True, node: 627, level: 12" node_number="627"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 628, level: 13" node_number="628">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 629, level: 12" node_number="629"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 630, level: 13" node_number="630">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 631, level: 12" node_number="631"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 632, level: 13" node_number="632">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 633, level: 12" node_number="633"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 634, level: 13" node_number="634">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 635, level: 13" node_number="635">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 636, level: 13" node_number="636">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 637, level: 12" node_number="637"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 638, level: 13" node_number="638">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 639, level: 13" node_number="639">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 640, level: 13" node_number="640">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 641, level: 12" node_number="641"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 642, level: 13" node_number="642">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 643, level: 13" node_number="643">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 644, level: 12" node_number="644"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 645, level: 13" node_number="645">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 646, level: 13" node_number="646">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 647, level: 13" node_number="647">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 648, level: 12" node_number="648"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 649, level: 13" node_number="649">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 650, level: 11" node_number="650"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 651, level: 12" node_number="651">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 652, level: 11" node_number="652"> <ul class="valid" valid="valid" title="valid: True, node: 653, level: 12" node_number="653"> <li class="valid" valid="valid" title="valid: True, node: 654, level: 13" node_number="654"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 655, level: 14" node_number="655"> <li title="valid: False, node: 656, level: 15" node_number="656"> Take XARELTO<sup title="valid: False, node: 657, level: 16" node_number="657">&#174;</sup> 1 time a day with your evening meal. </li> <li title="valid: False, node: 658, level: 15" node_number="658"> If you miss a dose of XARELTO<sup title="valid: False, node: 659, level: 16" node_number="659">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 660, level: 13" node_number="660"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 661, level: 14" node_number="661"> <li title="valid: False, node: 662, level: 15" node_number="662"> Take XARELTO<sup title="valid: False, node: 663, level: 16" node_number="663">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li title="valid: False, node: 664, level: 15" node_number="664"> For the 10-mg dose, XARELTO<sup title="valid: False, node: 665, level: 16" node_number="665">&#174;</sup> may be taken with or without food. </li> <li title="valid: False, node: 666, level: 15" node_number="666"> For the 15-mg and 20-mg doses, take XARELTO<sup title="valid: False, node: 667, level: 16" node_number="667">&#174;</sup> with food at the same time each day. </li> <li title="valid: False, node: 668, level: 15" node_number="668"> If you miss a dose: <ul title="valid: False, node: 669, level: 16" node_number="669"> <li title="valid: False, node: 670, level: 17" node_number="670"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 671, level: 18" node_number="671">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 672, level: 18" node_number="672">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 673, level: 18" node_number="673">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 674, level: 17" node_number="674"> If you take XARELTO<sup title="valid: False, node: 675, level: 18" node_number="675">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 676, level: 18" node_number="676">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 677, level: 13" node_number="677"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 678, level: 14" node_number="678"> <li title="valid: False, node: 679, level: 15" node_number="679"> Take XARELTO<sup title="valid: False, node: 680, level: 16" node_number="680">&#174;</sup> 1 time a day with or without food. </li> <li title="valid: False, node: 681, level: 15" node_number="681"> If you miss a dose of XARELTO<sup title="valid: False, node: 682, level: 16" node_number="682">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 683, level: 13" node_number="683"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 684, level: 14" node_number="684"> <li title="valid: False, node: 685, level: 15" node_number="685"> Take XARELTO<sup title="valid: False, node: 686, level: 16" node_number="686">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li title="valid: False, node: 687, level: 15" node_number="687"> If you miss a dose of XARELTO<sup title="valid: False, node: 688, level: 16" node_number="688">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 689, level: 13" node_number="689"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 690, level: 14" node_number="690"> <li title="valid: False, node: 691, level: 15" node_number="691"> Take XARELTO<sup title="valid: False, node: 692, level: 16" node_number="692">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li title="valid: False, node: 693, level: 15" node_number="693"> If you miss a dose of XARELTO<sup title="valid: False, node: 694, level: 16" node_number="694">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 695, level: 15" node_number="695"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 696, level: 11" node_number="696"> <p class="valid" valid="valid" title="valid: True, node: 697, level: 12" node_number="697"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 698, level: 13" node_number="698">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 699, level: 14" node_number="699">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 700, level: 12" node_number="700"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 701, level: 13" node_number="701">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 702, level: 12" node_number="702"> <li class="valid" valid="valid" title="valid: True, node: 703, level: 13" node_number="703"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 704, level: 14" node_number="704">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 705, level: 12" node_number="705"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 706, level: 13" node_number="706">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 707, level: 12" node_number="707"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 708, level: 12" node_number="708"> Please read full <a class="valid" valid="valid" title="valid: True, node: 709, level: 13" node_number="709">Prescribing Information</a>, including Boxed Warnings, and <a class="valid" valid="valid" title="valid: True, node: 710, level: 13" node_number="710">Medication Guide</a> for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 711, level: 13" node_number="711">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 712, level: 12" node_number="712"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 713, level: 12" node_number="713"> cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>